Invitrogen puts up $57M for CellzDirect buyout

Invitrogen is buying out CellzDirect in a $57 million cash deal. CellzDirect provides R&D operations hepatocyte-based cell products and other services used to test new drugs. Primary human hepatocytes can be used to predict a compound's effects on enzymatic metabolism in the liver, helping to avoid trial failures. CellzDirect was set up seven years ago and has facilities in North Carolina and Austin.

- check out the release for more info

Suggested Articles

Vital strategies for steriles development to ensure more flexibility within drug development.

After Mallinckrodt's terlipressin beat placebo at reversing kidney failure, an FDA panel will discuss the phase 3 trial's surrogate endpoint.

Operation Warp Speed is living up to its name as AstraZeneca is teaming up with IQVIA to boost its R&D for its pandemic shot.